Form 4: Director Boosts TOI Stake with $83,750 Stock Purchase

Oncology Institute Director and 10% owner Jorey Chernett acquired 25,000 shares of common stock for $3.35 per share in a pre-planned transaction.

Summary

• Jorey Chernett, a Director and 10% owner of Oncology Institute, Inc. (TOI), purchased 25,000 shares of common stock.
• The transaction occurred on March 20, 2026, at a weighted average price of $3.35 per share.
• The total value of the purchase was approximately $83,750 (25,000 shares * $3.35/share).
• Following this transaction, Mr. Chernett directly beneficially owns 10,276,929 shares of TOI common stock.
• The purchase was made pursuant to a Rule 10b5-1(c) pre-planned trading arrangement.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as a director and significant owner increasing their stake suggests confidence in the company's future performance and current valuation.

Positives

• A Director and 10% owner, Jorey Chernett, increased his direct beneficial ownership by purchasing 25,000 shares of common stock.
• Insider buying can signal confidence in the company's future prospects and valuation.

Negatives

• No explicit negatives are present in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider buying, especially from a significant shareholder and director like Jorey Chernett, often indicates a belief in the company's undervaluation or strong future prospects within the oncology sector. This move could be interpreted by the market as a positive signal, potentially influencing investor sentiment for Oncology Institute, Inc. (TOI) relative to its peers.

Related Party Transactions

• The purchase of 25,000 shares of common stock by Jorey Chernett, a Director and 10% owner, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive signal, potentially increasing confidence and demand for the stock.
• Management/Employees: Could boost morale and reinforce belief in the company's direction.

Next Steps

• This Form 4 filing does not explicitly mention any future actions, events, or milestones.

Key Dates

Recommendation

The significant purchase of shares by a Director and 10% owner, Jorey Chernett, signals strong insider confidence in Oncology Institute, Inc.'s future prospects and current valuation. Such insider buying often precedes positive company developments or reflects a belief that the stock is undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

Oncology Institute, TOI, Insider Buying, Form 4, Jorey Chernett, Director Purchase, Stock Acquisition, 10b5-1 Plan